Portal de Periódicos da CAPES

Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments

2020; BMJ; Volume: 80; Issue: 6 Linguagem: Inglês

10.1136/annrheumdis-2020-218244

1468-2060

Z. Gendebien, Christian Von Frenckell, Clio Ribbens, Béatrice André, Marie Thys, Marjorie Gangolf, Laurence Seidel, Michel Malaise, Olivier Malaise,

Long-Term Effects of COVID-19

Table 1 COVID-19 infection, suspicion and symptoms among patients with systemic lupus erythematosus (n=225) Variable Categories N (Percent) Variable Categories N (Percent) Dyspnea No 212 (94.2) COVID-19 infection confirmed or suspect by medical team No 207 (92.0)Yes 13 (5.8)Yes 18 (8.0)Chest pain No 214 (95.1)Positive nasopharyngeal PCR No 220 (97.8)Yes 11 (4.9)Yes 5 (2.2) Rhinorrhea No 200 (88.9)Admission to emergency department (without hospitalization) for COVID-19 symptoms No 218 (96.9)Yes 25 (11.1)Yes 7 (3.1)Pharyngeal pain No 205 (91.1)Hospitalization for COVID-19 symptoms No 223 (99.1)Yes 20 (8.9) Yes 2 (0.9) Cough No 203 (90.2) Suspicion of COVID-19 in ambulatory medicine No 211 (93.8)Yes 22 (9.8)Yes 14 (6.2) Diarrhea No 201 (89.3)Yes 24 (10.7)Headache No 191 (84.9)Ageusia No 211 (93.8)Yes 34 (15.1)Yes 14 (6.2) Myalgia No 209 (92.9)Anosmia No 211 (93.8)Yes 16 (7.1)Yes 14 (6.2) Fever No 214 (95.1)Ageusia or anosmia No 208 (92.4) Yes 11 (4.9)Yes 17 (7.6)Vomiting No 220 (97.8)Ageusia and anosmia No 214 (95.1)Yes 5 (2.2) Yes 11 (4.9)